You might know Jennifer Doudna as the Nobel Prize-winning pioneer of CRISPR genome editing, the subject of Walter Isaacson’s last book, or as a professor at the University of California Berkeley, among other titles. Now she’s adding another to the list: chief science advisor to the Wall Street firm Sixth Street, where she’s expected to help guide investment decisions related to the breakthrough technology she discovered.
Sixth Street manages about $60 billion in assets, and its vice chairman is Marty Chavez, a former C-level executive at Goldman Sachs who’s also on the board of the Broad Institute and serves on the Stanford Medicine Board of Fellows.
Create a display name to comment
This name will appear with your comment